These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model. Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357 [TBL] [Abstract][Full Text] [Related]
7. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo. Yukita A; Asano M; Okamoto T; Mizutani S; Suzuki H Anticancer Res; 2000; 20(1A):155-60. PubMed ID: 10769648 [TBL] [Abstract][Full Text] [Related]
8. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49. Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364 [TBL] [Abstract][Full Text] [Related]
9. The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy. Ward B; Mather S; Shepherd J; Crowther M; Hawkins L; Britton K; Slevin ML Br J Cancer; 1988 Nov; 58(5):658-62. PubMed ID: 3219277 [TBL] [Abstract][Full Text] [Related]
11. Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration. Ward BG; Mather SJ; Hawkins LR; Crowther ME; Shepherd JH; Granowska M; Britton KE; Slevin ML Cancer Res; 1987 Sep; 47(17):4719-23. PubMed ID: 3621168 [TBL] [Abstract][Full Text] [Related]
12. Antibody-guided irradiation of malignant lesions: three cases illustrating a new method of treatment. A report from the Hammersmith Oncology Group and the Imperial Cancer Research Fund. Lancet; 1984 Jun; 1(8392):1441-3. PubMed ID: 6145882 [TBL] [Abstract][Full Text] [Related]
13. Comparison of antigen expression on fresh and cultured ascites cells and on solid tumors of patients with epithelial ovarian cancer. Provencher DM; Finstad CL; Saigo PE; Rubin SC; Hoskins WJ; Federici MG; Stockert E; Lloyd KO; Lewis JL Gynecol Oncol; 1993 Jul; 50(1):78-83. PubMed ID: 8349167 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35. Elgqvist J; Andersson H; Bäck T; Hultborn R; Jensen H; Karlsson B; Lindegren S; Palm S; Warnhammar E; Jacobsson L J Nucl Med; 2005 Nov; 46(11):1907-15. PubMed ID: 16269606 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, biodistribution, and dosimetry of specific and control radiolabeled monoclonal antibodies in patients with primary head and neck squamous cell carcinoma. Maraveyas A; Stafford N; Rowlinson-Busza G; Stewart JS; Epenetos AA Cancer Res; 1995 Mar; 55(5):1060-9. PubMed ID: 7866989 [TBL] [Abstract][Full Text] [Related]
16. Radioimmunotherapy of human colon cancer xenografts by using 131I labeled-CAb1 F(ab')2. Li L; Xu HY; Mi L; Bian HJ; Qin J; Xiong H; Feng Q; Wen N; Tian R; Xu LQ; Shen XM; Tang H; Chen ZN Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1238-44. PubMed ID: 16979831 [TBL] [Abstract][Full Text] [Related]
17. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Mahé MA; Fumoleau P; Fabbro M; Guastalla JP; Faurous P; Chauvot P; Chetanoud L; Classe JM; Rouanet P; Chatal JF Clin Cancer Res; 1999 Oct; 5(10 Suppl):3249s-3253s. PubMed ID: 10541371 [TBL] [Abstract][Full Text] [Related]
18. Malignant ascites: review of the literature, and an update on monoclonal antibody-targeted therapy. Hird V; Thomas H; Stewart JS; Epenetos AA Eur J Obstet Gynecol Reprod Biol; 1989 Jul; 32(1):37-45. PubMed ID: 2670627 [TBL] [Abstract][Full Text] [Related]
19. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120 [TBL] [Abstract][Full Text] [Related]
20. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anti-carcinoembryonic antigen monoclonal antibodies. Juweid M; Swayne LC; Sharkey RM; Dunn R; Rubin AD; Herskovic T; Goldenberg DM Gynecol Oncol; 1997 Dec; 67(3):259-71. PubMed ID: 9441773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]